StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report published on Monday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NeuroMetrix stock opened at $3.81 on Monday. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The stock’s 50-day moving average is $4.04 and its 200 day moving average is $3.89.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share (EPS) for the quarter. The company had revenue of $0.77 million for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.